In a research report released Thursday, Cantor analyst Irina Rivkind maintained a Buy rating on Synergy Pharmaceuticals (NASDAQ:SGYP) and slightly raised her price target to $8.50 …
In a research report issued today, Roth Capital analyst Scott Henry reiterated a Buy rating on Synergy Pharmaceuticals (NASDAQ:SGYP), but reduced his price …
In a research report released today, Cantor analyst Irina Rivkind reiterated a Buy rating on Synergy Pharmaceuticals (NASDAQ:SGYP) with an $8 price target, following the …
Cantor analyst Irina Rivkind maintained a Buy rating on Synergy Pharmaceuticals (NASDAQ:SGYP) but reduced her price target to $8 (from $11), which represents a potential …
In a research report released Tuesday, analyst Irina Rivkind of Cantor assigned a Buy rating on Synergy Pharmaceuticals (NASDAQ:SGYP) with an $11 price target, following the presentation of results …
In a research report sent to investors today, Cantor Fitzgerald analyst Irina Rivkind reiterated a Buy rating on Synergy Pharmaceuticals (NASDAQ:SGYP) with a $11 price target, as the …
In a research report released today, Roth Capital analyst Scott Henry maintained coverage with a Buy rating on Synergy Pharmaceuticals (SGYP), and a $8.50 price target, following the company’s second …
In a research report released today, Cantor Fitzgerald analyst Irina Rivkind maintained a Buy rating on Synergy Pharmaceuticals (SGYP), with a $11 price target. The report follows the company’s …
